Serum level of MMP-9 and the MMP-9/TIMP-1 ratio were proven to be useful biomarkers in various courses of MS [123], and they were lowered by treatment with interferon-β, a drug commonly used for MS [108]. Here, TIMP1 is linked to myeloid sarcoma.